Treatment with the anti-IL-6 receptor antibody attenuates muscular dystrophy via promoting skeletal muscle regeneration in dystrophin-/utrophin-deficient mice

Chronic increases in the levels of the inflammatory cytokine interleukin-6 (IL-6) in serum and skeletal muscle are thought to contribute to the progression of muscular dystrophy. Dystrophin/utrophin double-knockout (dKO) mice develop a more severe and progressive muscular dystrophy than the mdx mice...

Full description

Saved in:
Bibliographic Details
Published inSkeletal muscle Vol. 7; no. 1; pp. 23 - 15
Main Authors Wada, Eiji, Tanihata, Jun, Iwamura, Akira, Takeda, Shin’ichi, Hayashi, Yukiko K., Matsuda, Ryoichi
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 27.10.2017
BioMed Central
BMC
Subjects
Animal models
Arthritis
Cardiac muscle
Care and treatment
Creatine
Creatine kinase
Cytokines
Degeneration
Diaphragm
Disease
Drug dosages
Duchenne muscular dystrophy
Duchenne's muscular dystrophy
Dystrophin
Embryos
Fibrosis
Health aspects
Immunoglobulin G
Inflammation
Inflammatory diseases
Interleukin 6
Interleukin 6 receptors
Kyphosis
Metabolism
Muscle regeneration
Muscular dystrophy
Musculoskeletal system
Myosin
Pathology
Physiological aspects
Quadriceps muscle
Rats
Rodents
Skeletal muscle
STAT3
Stem cells
Tissue engineering
Transcription
Transgenic animals
Utrophin
Vertebrae
Duchenne muscular dystrophy
Muscle regeneration
Fibrosis
STAT3
Interleukin-6
Online AccessGet full text

Cover

Abstract Chronic increases in the levels of the inflammatory cytokine interleukin-6 (IL-6) in serum and skeletal muscle are thought to contribute to the progression of muscular dystrophy. Dystrophin/utrophin double-knockout (dKO) mice develop a more severe and progressive muscular dystrophy than the mdx mice, the most common murine model of Duchenne muscular dystrophy (DMD). In particular, dKO mice have smaller body sizes and muscle diameters, and develop progressive kyphosis and fibrosis in skeletal and cardiac muscles. As mdx mice and DMD patients, we found that IL-6 levels in the skeletal muscle were significantly increased in dKO mice. Thus, in this study, we aimed to analyze the effects of IL-6 receptor (IL-6R) blockade on the muscle pathology of dKO mice. Male dKO mice were administered an initial injection (200 mg/kg intraperitoneally (i.p.)) of either the anti-IL-6R antibody MR16-1 or an isotype-matched control rat IgG at the age of 14 days, and were then given weekly injections (25 mg/kg i.p.) until 90 days of age. Treatment of dKO mice with the MR16-1 antibody successfully inhibited the IL-6 pathway in the skeletal muscle and resulted in a significant reduction in the expression levels of phosphorylated signal transducer and activator of transcription 3 in the skeletal muscle. Pathologically, a significant increase in the area of embryonic myosin heavy chain-positive myofibers and muscle diameter, and reduced fibrosis in the quadriceps muscle were observed. These results demonstrated the therapeutic effects of IL-6R blockade on promoting muscle regeneration. Consistently, serum creatine kinase levels were decreased. Despite these improvements observed in the limb muscles, degeneration of the diaphragm and cardiac muscles was not ameliorated by the treatment of mice with the MR16-1 antibody. As no adverse effects of treatment with the MR16-1 antibody were observed, our results indicate that the anti-IL-6R antibody is a potential therapy for muscular dystrophy particularly for promoting skeletal muscle regeneration.
AbstractList Abstract Background Chronic increases in the levels of the inflammatory cytokine interleukin-6 (IL-6) in serum and skeletal muscle are thought to contribute to the progression of muscular dystrophy. Dystrophin/utrophin double-knockout (dKO) mice develop a more severe and progressive muscular dystrophy than the mdx mice, the most common murine model of Duchenne muscular dystrophy (DMD). In particular, dKO mice have smaller body sizes and muscle diameters, and develop progressive kyphosis and fibrosis in skeletal and cardiac muscles. As mdx mice and DMD patients, we found that IL-6 levels in the skeletal muscle were significantly increased in dKO mice. Thus, in this study, we aimed to analyze the effects of IL-6 receptor (IL-6R) blockade on the muscle pathology of dKO mice. Methods Male dKO mice were administered an initial injection (200 mg/kg intraperitoneally (i.p.)) of either the anti-IL-6R antibody MR16-1 or an isotype-matched control rat IgG at the age of 14 days, and were then given weekly injections (25 mg/kg i.p.) until 90 days of age. Results Treatment of dKO mice with the MR16-1 antibody successfully inhibited the IL-6 pathway in the skeletal muscle and resulted in a significant reduction in the expression levels of phosphorylated signal transducer and activator of transcription 3 in the skeletal muscle. Pathologically, a significant increase in the area of embryonic myosin heavy chain-positive myofibers and muscle diameter, and reduced fibrosis in the quadriceps muscle were observed. These results demonstrated the therapeutic effects of IL-6R blockade on promoting muscle regeneration. Consistently, serum creatine kinase levels were decreased. Despite these improvements observed in the limb muscles, degeneration of the diaphragm and cardiac muscles was not ameliorated by the treatment of mice with the MR16-1 antibody. Conclusion As no adverse effects of treatment with the MR16-1 antibody were observed, our results indicate that the anti-IL-6R antibody is a potential therapy for muscular dystrophy particularly for promoting skeletal muscle regeneration.
Chronic increases in the levels of the inflammatory cytokine interleukin-6 (IL-6) in serum and skeletal muscle are thought to contribute to the progression of muscular dystrophy. Dystrophin/utrophin double-knockout (dKO) mice develop a more severe and progressive muscular dystrophy than the mdx mice, the most common murine model of Duchenne muscular dystrophy (DMD). In particular, dKO mice have smaller body sizes and muscle diameters, and develop progressive kyphosis and fibrosis in skeletal and cardiac muscles. As mdx mice and DMD patients, we found that IL-6 levels in the skeletal muscle were significantly increased in dKO mice. Thus, in this study, we aimed to analyze the effects of IL-6 receptor (IL-6R) blockade on the muscle pathology of dKO mice. Male dKO mice were administered an initial injection (200 mg/kg intraperitoneally (i.p.)) of either the anti-IL-6R antibody MR16-1 or an isotype-matched control rat IgG at the age of 14 days, and were then given weekly injections (25 mg/kg i.p.) until 90 days of age. Treatment of dKO mice with the MR16-1 antibody successfully inhibited the IL-6 pathway in the skeletal muscle and resulted in a significant reduction in the expression levels of phosphorylated signal transducer and activator of transcription 3 in the skeletal muscle. Pathologically, a significant increase in the area of embryonic myosin heavy chain-positive myofibers and muscle diameter, and reduced fibrosis in the quadriceps muscle were observed. These results demonstrated the therapeutic effects of IL-6R blockade on promoting muscle regeneration. Consistently, serum creatine kinase levels were decreased. Despite these improvements observed in the limb muscles, degeneration of the diaphragm and cardiac muscles was not ameliorated by the treatment of mice with the MR16-1 antibody. As no adverse effects of treatment with the MR16-1 antibody were observed, our results indicate that the anti-IL-6R antibody is a potential therapy for muscular dystrophy particularly for promoting skeletal muscle regeneration.
Background Chronic increases in the levels of the inflammatory cytokine interleukin-6 (IL-6) in serum and skeletal muscle are thought to contribute to the progression of muscular dystrophy. Dystrophin/utrophin double-knockout (dKO) mice develop a more severe and progressive muscular dystrophy than the mdx mice, the most common murine model of Duchenne muscular dystrophy (DMD). In particular, dKO mice have smaller body sizes and muscle diameters, and develop progressive kyphosis and fibrosis in skeletal and cardiac muscles. As mdx mice and DMD patients, we found that IL-6 levels in the skeletal muscle were significantly increased in dKO mice. Thus, in this study, we aimed to analyze the effects of IL-6 receptor (IL-6R) blockade on the muscle pathology of dKO mice. Methods Male dKO mice were administered an initial injection (200 mg/kg intraperitoneally (i.p.)) of either the anti-IL-6R antibody MR16-1 or an isotype-matched control rat IgG at the age of 14 days, and were then given weekly injections (25 mg/kg i.p.) until 90 days of age. Results Treatment of dKO mice with the MR16-1 antibody successfully inhibited the IL-6 pathway in the skeletal muscle and resulted in a significant reduction in the expression levels of phosphorylated signal transducer and activator of transcription 3 in the skeletal muscle. Pathologically, a significant increase in the area of embryonic myosin heavy chain-positive myofibers and muscle diameter, and reduced fibrosis in the quadriceps muscle were observed. These results demonstrated the therapeutic effects of IL-6R blockade on promoting muscle regeneration. Consistently, serum creatine kinase levels were decreased. Despite these improvements observed in the limb muscles, degeneration of the diaphragm and cardiac muscles was not ameliorated by the treatment of mice with the MR16-1 antibody. Conclusion As no adverse effects of treatment with the MR16-1 antibody were observed, our results indicate that the anti-IL-6R antibody is a potential therapy for muscular dystrophy particularly for promoting skeletal muscle regeneration. Keywords: Interleukin-6, Duchenne muscular dystrophy, STAT3, Muscle regeneration, Fibrosis
BackgroundChronic increases in the levels of the inflammatory cytokine interleukin-6 (IL-6) in serum and skeletal muscle are thought to contribute to the progression of muscular dystrophy. Dystrophin/utrophin double-knockout (dKO) mice develop a more severe and progressive muscular dystrophy than the mdx mice, the most common murine model of Duchenne muscular dystrophy (DMD). In particular, dKO mice have smaller body sizes and muscle diameters, and develop progressive kyphosis and fibrosis in skeletal and cardiac muscles. As mdx mice and DMD patients, we found that IL-6 levels in the skeletal muscle were significantly increased in dKO mice. Thus, in this study, we aimed to analyze the effects of IL-6 receptor (IL-6R) blockade on the muscle pathology of dKO mice.MethodsMale dKO mice were administered an initial injection (200 mg/kg intraperitoneally (i.p.)) of either the anti-IL-6R antibody MR16-1 or an isotype-matched control rat IgG at the age of 14 days, and were then given weekly injections (25 mg/kg i.p.) until 90 days of age.ResultsTreatment of dKO mice with the MR16-1 antibody successfully inhibited the IL-6 pathway in the skeletal muscle and resulted in a significant reduction in the expression levels of phosphorylated signal transducer and activator of transcription 3 in the skeletal muscle. Pathologically, a significant increase in the area of embryonic myosin heavy chain-positive myofibers and muscle diameter, and reduced fibrosis in the quadriceps muscle were observed. These results demonstrated the therapeutic effects of IL-6R blockade on promoting muscle regeneration. Consistently, serum creatine kinase levels were decreased. Despite these improvements observed in the limb muscles, degeneration of the diaphragm and cardiac muscles was not ameliorated by the treatment of mice with the MR16-1 antibody.ConclusionAs no adverse effects of treatment with the MR16-1 antibody were observed, our results indicate that the anti-IL-6R antibody is a potential therapy for muscular dystrophy particularly for promoting skeletal muscle regeneration.
Chronic increases in the levels of the inflammatory cytokine interleukin-6 (IL-6) in serum and skeletal muscle are thought to contribute to the progression of muscular dystrophy. Dystrophin/utrophin double-knockout (dKO) mice develop a more severe and progressive muscular dystrophy than the mdx mice, the most common murine model of Duchenne muscular dystrophy (DMD). In particular, dKO mice have smaller body sizes and muscle diameters, and develop progressive kyphosis and fibrosis in skeletal and cardiac muscles. As mdx mice and DMD patients, we found that IL-6 levels in the skeletal muscle were significantly increased in dKO mice. Thus, in this study, we aimed to analyze the effects of IL-6 receptor (IL-6R) blockade on the muscle pathology of dKO mice.BACKGROUNDChronic increases in the levels of the inflammatory cytokine interleukin-6 (IL-6) in serum and skeletal muscle are thought to contribute to the progression of muscular dystrophy. Dystrophin/utrophin double-knockout (dKO) mice develop a more severe and progressive muscular dystrophy than the mdx mice, the most common murine model of Duchenne muscular dystrophy (DMD). In particular, dKO mice have smaller body sizes and muscle diameters, and develop progressive kyphosis and fibrosis in skeletal and cardiac muscles. As mdx mice and DMD patients, we found that IL-6 levels in the skeletal muscle were significantly increased in dKO mice. Thus, in this study, we aimed to analyze the effects of IL-6 receptor (IL-6R) blockade on the muscle pathology of dKO mice.Male dKO mice were administered an initial injection (200 mg/kg intraperitoneally (i.p.)) of either the anti-IL-6R antibody MR16-1 or an isotype-matched control rat IgG at the age of 14 days, and were then given weekly injections (25 mg/kg i.p.) until 90 days of age.METHODSMale dKO mice were administered an initial injection (200 mg/kg intraperitoneally (i.p.)) of either the anti-IL-6R antibody MR16-1 or an isotype-matched control rat IgG at the age of 14 days, and were then given weekly injections (25 mg/kg i.p.) until 90 days of age.Treatment of dKO mice with the MR16-1 antibody successfully inhibited the IL-6 pathway in the skeletal muscle and resulted in a significant reduction in the expression levels of phosphorylated signal transducer and activator of transcription 3 in the skeletal muscle. Pathologically, a significant increase in the area of embryonic myosin heavy chain-positive myofibers and muscle diameter, and reduced fibrosis in the quadriceps muscle were observed. These results demonstrated the therapeutic effects of IL-6R blockade on promoting muscle regeneration. Consistently, serum creatine kinase levels were decreased. Despite these improvements observed in the limb muscles, degeneration of the diaphragm and cardiac muscles was not ameliorated by the treatment of mice with the MR16-1 antibody.RESULTSTreatment of dKO mice with the MR16-1 antibody successfully inhibited the IL-6 pathway in the skeletal muscle and resulted in a significant reduction in the expression levels of phosphorylated signal transducer and activator of transcription 3 in the skeletal muscle. Pathologically, a significant increase in the area of embryonic myosin heavy chain-positive myofibers and muscle diameter, and reduced fibrosis in the quadriceps muscle were observed. These results demonstrated the therapeutic effects of IL-6R blockade on promoting muscle regeneration. Consistently, serum creatine kinase levels were decreased. Despite these improvements observed in the limb muscles, degeneration of the diaphragm and cardiac muscles was not ameliorated by the treatment of mice with the MR16-1 antibody.As no adverse effects of treatment with the MR16-1 antibody were observed, our results indicate that the anti-IL-6R antibody is a potential therapy for muscular dystrophy particularly for promoting skeletal muscle regeneration.CONCLUSIONAs no adverse effects of treatment with the MR16-1 antibody were observed, our results indicate that the anti-IL-6R antibody is a potential therapy for muscular dystrophy particularly for promoting skeletal muscle regeneration.
Chronic increases in the levels of the inflammatory cytokine interleukin-6 (IL-6) in serum and skeletal muscle are thought to contribute to the progression of muscular dystrophy. Dystrophin/utrophin double-knockout (dKO) mice develop a more severe and progressive muscular dystrophy than the mdx mice, the most common murine model of Duchenne muscular dystrophy (DMD). In particular, dKO mice have smaller body sizes and muscle diameters, and develop progressive kyphosis and fibrosis in skeletal and cardiac muscles. As mdx mice and DMD patients, we found that IL-6 levels in the skeletal muscle were significantly increased in dKO mice. Thus, in this study, we aimed to analyze the effects of IL-6 receptor (IL-6R) blockade on the muscle pathology of dKO mice. Male dKO mice were administered an initial injection (200 mg/kg intraperitoneally (i.p.)) of either the anti-IL-6R antibody MR16-1 or an isotype-matched control rat IgG at the age of 14 days, and were then given weekly injections (25 mg/kg i.p.) until 90 days of age. Treatment of dKO mice with the MR16-1 antibody successfully inhibited the IL-6 pathway in the skeletal muscle and resulted in a significant reduction in the expression levels of phosphorylated signal transducer and activator of transcription 3 in the skeletal muscle. Pathologically, a significant increase in the area of embryonic myosin heavy chain-positive myofibers and muscle diameter, and reduced fibrosis in the quadriceps muscle were observed. These results demonstrated the therapeutic effects of IL-6R blockade on promoting muscle regeneration. Consistently, serum creatine kinase levels were decreased. Despite these improvements observed in the limb muscles, degeneration of the diaphragm and cardiac muscles was not ameliorated by the treatment of mice with the MR16-1 antibody. As no adverse effects of treatment with the MR16-1 antibody were observed, our results indicate that the anti-IL-6R antibody is a potential therapy for muscular dystrophy particularly for promoting skeletal muscle regeneration.
ArticleNumber 23
Audience Academic
Author Wada, Eiji
Takeda, Shin’ichi
Matsuda, Ryoichi
Tanihata, Jun
Hayashi, Yukiko K.
Iwamura, Akira
Author_xml – sequence: 1
  givenname: Eiji
  orcidid: 0000-0002-9139-9621
  surname: Wada
  fullname: Wada, Eiji
– sequence: 2
  givenname: Jun
  surname: Tanihata
  fullname: Tanihata, Jun
– sequence: 3
  givenname: Akira
  surname: Iwamura
  fullname: Iwamura, Akira
– sequence: 4
  givenname: Shin’ichi
  surname: Takeda
  fullname: Takeda, Shin’ichi
– sequence: 5
  givenname: Yukiko K.
  surname: Hayashi
  fullname: Hayashi, Yukiko K.
– sequence: 6
  givenname: Ryoichi
  surname: Matsuda
  fullname: Matsuda, Ryoichi
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29078808$$D View this record in MEDLINE/PubMed
BookMark eNp1Ul1vFCEUnZgaW2t_gC9mEl_0YVpYYJh5MWkaPzbZxETrMwHmsss6Aysw1e2P8bfK7nZrt1EIgVzOOdx7Oc-LI-cdFMVLjM4xbuqLiAlpWYUwz4ui6vZJcTJBlFYMUXT04HxcnMW4RHnQFiPePCuOJ23eG9ScFL-vA8g0gEvlT5sWZVpAKV2y1XRW1WUADavkwzakfLcuZUrgRpkglsMY9djLUHbrmIJfLdbljZXlKvjBJ-vmZfwOPSTZb5E9ZLU5OAgyWe9K6-551lUX4_7UgbHabvIZrIYXxVMj-whnd_tp8e3D--urT9Xs88fp1eWs0qylqeoIqxUmCgyVE4IYabpOApJAaq2YMroxoHK9jPNWUSIpIMZNp7VBRirGyWkx3el2Xi7FKthBhrXw0optwIe5kCHZXIXgqG1VywmpzYRq3EmOqFIK6xZ13BDIWu92WqtRDdDpXEuQ_YHo4Y2zCzH3N4LVNaKMZoE3dwLB_xghJjHYqKHvpQM_RoFbxmn-wRZn6OtH0KUfg8utyqg6Z4oRbf6i5jIXYJ3x-V29ERWXDGPeMlRvenD-D1SeHeSvyOYzNscPCG8PCBmT4FeayzFGMf365RD76mFT7ruxd2IG8B1ABx9jACO0TVur5CxsLzASG9uLne1Ftr3Y2F7cZiZ-xNyL_5_zB-mZB-U
CitedBy_id crossref_primary_10_1096_fj_202200848R
crossref_primary_10_1016_j_metabol_2023_155597
crossref_primary_10_1152_ajpcell_00196_2023
crossref_primary_10_3390_cells14020116
crossref_primary_10_3390_metabo12070631
crossref_primary_10_1016_j_bioelechem_2023_108487
crossref_primary_10_1016_j_celrep_2020_107597
crossref_primary_10_1002_rco2_23
crossref_primary_10_1089_ars_2024_0620
crossref_primary_10_3390_ijms19082265
crossref_primary_10_1177_1759720X211015006
crossref_primary_10_3390_ijms21218261
crossref_primary_10_1016_j_ejphar_2024_176910
crossref_primary_10_1016_j_clnesp_2024_04_014
crossref_primary_10_1016_j_peptides_2022_170840
crossref_primary_10_1016_j_ymthe_2019_08_016
crossref_primary_10_3389_fphys_2019_00042
crossref_primary_10_3390_ijms20215273
crossref_primary_10_1007_s11926_018_0712_x
crossref_primary_10_3389_fendo_2020_606947
crossref_primary_10_1016_j_mehy_2022_110780
crossref_primary_10_3390_jfmk2040044
crossref_primary_10_3389_fphar_2022_1031906
crossref_primary_10_1016_j_lfs_2018_09_043
crossref_primary_10_3390_cells8030232
crossref_primary_10_1186_s12885_021_09004_y
crossref_primary_10_1371_journal_pone_0221512
crossref_primary_10_1155_2020_8672939
crossref_primary_10_1093_jas_skac311
crossref_primary_10_3390_ijms252212425
crossref_primary_10_3389_fcell_2023_1173794
crossref_primary_10_3233_JND_210737
crossref_primary_10_3389_fendo_2024_1398050
crossref_primary_10_3390_ijms22136669
crossref_primary_10_3390_metabo14060340
crossref_primary_10_1007_s11914_018_0468_2
crossref_primary_10_1016_j_scispo_2019_02_002
crossref_primary_10_47360_1995_4484_2024_81_89
crossref_primary_10_1111_bph_15678
crossref_primary_10_3389_fphar_2021_635654
crossref_primary_10_1113_JP276954
crossref_primary_10_3390_cells9051297
crossref_primary_10_1016_j_gpb_2020_06_004
crossref_primary_10_1016_j_stem_2018_10_006
crossref_primary_10_1007_s12041_022_01410_w
crossref_primary_10_1016_j_biomaterials_2020_120435
crossref_primary_10_1016_j_coph_2022_102332
crossref_primary_10_3390_ijms21134596
Cites_doi 10.1016/0092-8674(87)90579-4
10.1002/jor.22236
10.1016/j.pediatrneurol.2006.09.016
10.1002/bdrb.21053
10.1016/j.intimp.2008.07.002
10.1016/j.ebiom.2015.02.014
10.1038/ncb2014
10.1007/s00401-004-0941-0
10.1002/jbmr.410
10.1371/journal.pone.0010763
10.1038/nm.3656
10.1152/japplphysiol.01357.2003
10.1093/hmg/ddn376
10.2147/DDDT.S110163
10.1097/NEN.0b013e3181e9a34b
10.1371/journal.pone.0117306
10.1371/journal.pone.0118080
10.1212/WNL.0000000000000317
10.1074/jbc.273.22.13625
10.1186/1471-2474-13-106
10.1182/blood-2008-05-155846
10.1186/s12885-016-2305-2
10.1111/febs.12338
10.1007/BF00275183
10.1073/pnas.91.18.8307
10.3899/jrheum.121389
10.3181/00379727-205-43695
10.1093/hmg/ddv323
10.1093/hmg/ddv055
10.1038/nm.3655
10.1038/jid.2012.226
10.1016/S0092-8674(00)80532-2
10.1007/s00296-010-1500-8
10.1186/2044-5040-1-21
10.1186/ar1917
10.1152/japplphysiol.01026.2004
10.1016/j.nmd.2008.11.015
10.1016/j.celrep.2016.07.041
10.1155/2014/965631
10.14814/phy2.12391
10.1073/pnas.1323842111
10.1016/j.ajpath.2014.07.007
10.1242/jcs.086629
10.1016/j.scr.2014.10.007
10.1093/hmg/ddu194
ContentType Journal Article
Copyright COPYRIGHT 2017 BioMed Central Ltd.
Copyright BioMed Central 2017
The Author(s). 2017
Copyright_xml – notice: COPYRIGHT 2017 BioMed Central Ltd.
– notice: Copyright BioMed Central 2017
– notice: The Author(s). 2017
DBID AAYXX
CITATION
NPM
ISR
3V.
7X7
7XB
88E
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s13395-017-0140-z
DatabaseName CrossRef
PubMed
Gale In Context: Science
ProQuest Central (Corporate)
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials Local Electronic Collection Information
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection (UHCL Subscription)
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList



Publicly Available Content Database
MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
EISSN 2044-5040
EndPage 15
ExternalDocumentID oai_doaj_org_article_7099b97336f24c1da704bbb1c90d7f3e
PMC5660454
A511795067
29078808
10_1186_s13395_017_0140_z
Genre Journal Article
GroupedDBID 0R~
4.4
53G
5VS
7X7
88E
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFS
ACUHS
ADBBV
ADRAZ
ADUKV
AENEX
AFKRA
AFPKN
AHBYD
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AOIJS
BAWUL
BBNVY
BCNDV
BENPR
BFQNJ
BHPHI
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
DIK
EBD
EBLON
EBS
EJD
ESX
FYUFA
GROUPED_DOAJ
H13
HCIFZ
HMCUK
HYE
IAO
IGS
IHR
INH
INR
IPT
ISR
ITC
KQ8
LK8
M1P
M48
M7P
M~E
O5R
O5S
OK1
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
ROL
RPM
RSV
SMD
SOJ
TUS
U2A
UKHRP
-A0
3V.
ACRMQ
ADINQ
C24
NPM
PMFND
7XB
8FK
AHSBF
AZQEC
DWQXO
GNUQQ
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c594t-d356b13bef4a230538ddae0ae36cb5bfc8feb8085779b43a4e057fdccf0fab573
IEDL.DBID M48
ISSN 2044-5040
IngestDate Wed Aug 27 01:13:37 EDT 2025
Thu Aug 21 18:32:26 EDT 2025
Fri Jul 11 04:00:00 EDT 2025
Fri Jul 25 12:01:31 EDT 2025
Tue Jun 17 20:46:49 EDT 2025
Tue Jun 10 20:14:51 EDT 2025
Fri Jun 27 04:45:23 EDT 2025
Wed Feb 19 02:44:23 EST 2025
Tue Jul 01 04:33:27 EDT 2025
Thu Apr 24 22:51:24 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Duchenne muscular dystrophy
Muscle regeneration
Fibrosis
STAT3
Interleukin-6
Language English
License Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c594t-d356b13bef4a230538ddae0ae36cb5bfc8feb8085779b43a4e057fdccf0fab573
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-9139-9621
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s13395-017-0140-z
PMID 29078808
PQID 1960991048
PQPubID 2040191
PageCount 15
ParticipantIDs doaj_primary_oai_doaj_org_article_7099b97336f24c1da704bbb1c90d7f3e
pubmedcentral_primary_oai_pubmedcentral_nih_gov_5660454
proquest_miscellaneous_1957490791
proquest_journals_1960991048
gale_infotracmisc_A511795067
gale_infotracacademiconefile_A511795067
gale_incontextgauss_ISR_A511795067
pubmed_primary_29078808
crossref_citationtrail_10_1186_s13395_017_0140_z
crossref_primary_10_1186_s13395_017_0140_z
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2017-10-27
PublicationDateYYYYMMDD 2017-10-27
PublicationDate_xml – month: 10
  year: 2017
  text: 2017-10-27
  day: 27
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Skeletal muscle
PublicationTitleAlternate Skelet Muscle
PublicationYear 2017
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References M Wehling-Henricks (140_CR42) 2010; 5
EP Hoffman (140_CR2) 1987; 51
J Sohn (140_CR46) 2015; 24
M Noguchi-Sasaki (140_CR29) 2016; 16
A Uezumi (140_CR45) 2011; 124
A Rufo (140_CR12) 2011; 26
H Zhu (140_CR36) 2016; 16
CJ Mann (140_CR5) 2011; 1
P Muñoz-Cánoves (140_CR8) 2013; 280
CP Fischer (140_CR9) 2006; 12
N Deconinck (140_CR3) 2007; 36
E Wada (140_CR40) 2014; 184
N Laws (140_CR22) 2004; 97
L Zhou (140_CR43) 2010; 69
P Silacci (140_CR48) 1998; 273
F Haddad (140_CR11) 2005; 98
MN Goodman (140_CR10) 1994; 205
FD Price (140_CR34) 2014; 20
L Pelosi (140_CR13) 2015; 24
K Shimamoto (140_CR32) 2013; 40
C Gabay (140_CR7) 2006; 8 Suppl 2
D Le Huu (140_CR30) 2012; 132
Y Uchiyama (140_CR31) 2008; 8
SA Villalta (140_CR41) 2009; 18
N Nishimoto (140_CR33) 2008; 112
S Messina (140_CR6) 2011; 30
AE Deconinck (140_CR20) 1997; 90
JJ Belanto (140_CR18) 2014; 111
T Sakurai (140_CR28) 2013; 98
MC Kostek (140_CR14) 2012; 13
JM Tinsley (140_CR17) 1994; 91
A Isobe (140_CR26) 2015; 10
A Uezumi (140_CR44) 2010; 12
R Fujita (140_CR37) 1840; 2014
S Miyatake (140_CR24) 2016; 10
Y Shimizu-Motohashi (140_CR23) 2016; 8
H Yoshida (140_CR27) 2011; 31
Y Kharraz (140_CR4) 2014; 2014
X Mu (140_CR39) 2015; 24
L Boldrin (140_CR19) 2015; 14
A Lu (140_CR38) 2014; 23
M Araki (140_CR25) 2014; 82
KM Gutpell (140_CR50) 2015; 10
MT Tierney (140_CR35) 2014; 20
L Pelosi (140_CR15) 2015; 2
H Moser (140_CR1) 1984; 66
R Willmann (140_CR16) 2009; 19
A von Moers (140_CR47) 2005; 109
AA McDonald (140_CR49) 2015; 3
C Isaac (140_CR21) 2013; 31
21509823 - J Bone Miner Res. 2011 Aug;26(8):1891-903
9288751 - Cell. 1997 Aug 22;90(4):717-27
6365739 - Hum Genet. 1984;66(1):17-40
27398133 - Am J Transl Res. 2016 Jun 15;8(6):2471-89
17201070 - Exerc Immunol Rev. 2006;12:6-33
15234960 - J Appl Physiol (1985). 2004 Nov;97(5):1970-7
24440156 - Biochim Biophys Acta. 2014 Oct;1840(10):3170-80
21842588 - Acta Myol. 2011 Jun;30(1):16-23
24634453 - Neurology. 2014 Apr 15;82(15):1302-6
9593700 - J Biol Chem. 1998 May 29;273(22):13625-9
3319190 - Cell. 1987 Dec 24;51(6):919-28
27621596 - Drug Des Devel Ther. 2016 Aug 30;10 :2745-58
25460248 - Stem Cell Res. 2015 Jan;14(1):20-9
26251044 - Hum Mol Genet. 2015 Nov 1;24(21):6041-53
24781208 - Hum Mol Genet. 2014 Sep 15;23(18):4786-800
21798099 - Skelet Muscle. 2011 May 04;1(1):21
18996917 - Hum Mol Genet. 2009 Feb 1;18(3):482-96
15616792 - Acta Neuropathol. 2005 Mar;109(3):285-93
22716658 - BMC Musculoskelet Disord. 2012 Jun 20;13:106
16899107 - Arthritis Res Ther. 2006;8 Suppl 2:S3
22045730 - J Cell Sci. 2011 Nov 1;124(Pt 21):3654-64
22810302 - J Invest Dermatol. 2012 Dec;132(12):2752-61
25921779 - Physiol Rep. 2015 Apr;3(4):null
26137572 - EBioMedicine. 2015 Feb 26;2(4):285-93
23529913 - Birth Defects Res B Dev Reprod Toxicol. 2013 Apr;98(2):170-82
19217290 - Neuromuscul Disord. 2009 Apr;19(4):241-9
17162189 - Pediatr Neurol. 2007 Jan;36(1):1-7
20473503 - Rheumatol Int. 2011 Nov;31(11):1445-9
24877152 - Biomed Res Int. 2014;2014:965631
25859011 - Hum Mol Genet. 2015 Jul 1;24(13):3814-29
15542570 - J Appl Physiol (1985). 2005 Mar;98(3):911-7
24706788 - Proc Natl Acad Sci U S A. 2014 Apr 15;111(15):5723-8
27068103 - BMC Cancer. 2016 Apr 11;16:270
23637318 - J Rheumatol. 2013 Jul;40(7):1074-81
8108469 - Proc Soc Exp Biol Med. 1994 Feb;205(2):182-5
25678553 - Hum Mol Genet. 2015 May 15;24(10):2923-37
20081842 - Nat Cell Biol. 2010 Feb;12(2):143-52
25658637 - PLoS One. 2015 Feb 06;10(2):e0118080
25194572 - Nat Med. 2014 Oct;20(10):1182-6
20613637 - J Neuropathol Exp Neurol. 2010 Aug;69(8):771-6
8078878 - Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8307-13
23097179 - J Orthop Res. 2013 Mar;31(3):343-9
25194569 - Nat Med. 2014 Oct;20(10):1174-81
23663276 - FEBS J. 2013 Sep;280(17):4131-48
25607927 - PLoS One. 2015 Jan 21;10(1):e0117306
20505827 - PLoS One. 2010 May 21;5(5):e10763
27524611 - Cell Rep. 2016 Aug 23;16(8):2102-2115
18784373 - Blood. 2008 Nov 15;112(10 ):3959-64
25174878 - Am J Pathol. 2014 Nov;184(11):3094-104
18664393 - Int Immunopharmacol. 2008 Nov;8(11):1595-601
References_xml – volume: 51
  start-page: 919
  year: 1987
  ident: 140_CR2
  publication-title: Cell
  doi: 10.1016/0092-8674(87)90579-4
– volume: 31
  start-page: 343
  year: 2013
  ident: 140_CR21
  publication-title: J Orthop Res
  doi: 10.1002/jor.22236
– volume: 36
  start-page: 1
  year: 2007
  ident: 140_CR3
  publication-title: Pediatr Neurol
  doi: 10.1016/j.pediatrneurol.2006.09.016
– volume: 98
  start-page: 170
  year: 2013
  ident: 140_CR28
  publication-title: Birth Defects Res B Dev Reprod Toxicol
  doi: 10.1002/bdrb.21053
– volume: 2014
  start-page: 3170
  year: 1840
  ident: 140_CR37
  publication-title: Biochim Biophys Acta
– volume: 8
  start-page: 1595
  year: 2008
  ident: 140_CR31
  publication-title: Int Immunopharmacol
  doi: 10.1016/j.intimp.2008.07.002
– volume: 12
  start-page: 6
  year: 2006
  ident: 140_CR9
  publication-title: Exerc Immunol Rev
– volume: 2
  start-page: 285
  year: 2015
  ident: 140_CR15
  publication-title: EBioMedicine
  doi: 10.1016/j.ebiom.2015.02.014
– volume: 12
  start-page: 143
  year: 2010
  ident: 140_CR44
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb2014
– volume: 109
  start-page: 285
  year: 2005
  ident: 140_CR47
  publication-title: Acta Neuropathol
  doi: 10.1007/s00401-004-0941-0
– volume: 26
  start-page: 1891
  year: 2011
  ident: 140_CR12
  publication-title: J Bone Miner Res
  doi: 10.1002/jbmr.410
– volume: 5
  start-page: e10763
  year: 2010
  ident: 140_CR42
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0010763
– volume: 20
  start-page: 1182
  year: 2014
  ident: 140_CR35
  publication-title: Nat Med
  doi: 10.1038/nm.3656
– volume: 97
  start-page: 1970
  year: 2004
  ident: 140_CR22
  publication-title: J Appl Physiol (1985)
  doi: 10.1152/japplphysiol.01357.2003
– volume: 18
  start-page: 482
  year: 2009
  ident: 140_CR41
  publication-title: Hum Mol Genet
  doi: 10.1093/hmg/ddn376
– volume: 10
  start-page: 2745
  year: 2016
  ident: 140_CR24
  publication-title: Drug Des Devel Ther
  doi: 10.2147/DDDT.S110163
– volume: 69
  start-page: 771
  year: 2010
  ident: 140_CR43
  publication-title: J Neuropathol Exp Neurol
  doi: 10.1097/NEN.0b013e3181e9a34b
– volume: 10
  start-page: e0117306
  year: 2015
  ident: 140_CR50
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0117306
– volume: 10
  start-page: e0118080
  year: 2015
  ident: 140_CR26
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0118080
– volume: 82
  start-page: 1302
  year: 2014
  ident: 140_CR25
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000000317
– volume: 273
  start-page: 13625
  year: 1998
  ident: 140_CR48
  publication-title: J Biol Chem
  doi: 10.1074/jbc.273.22.13625
– volume: 13
  start-page: 106
  year: 2012
  ident: 140_CR14
  publication-title: BMC Musculoskelet Disord
  doi: 10.1186/1471-2474-13-106
– volume: 112
  start-page: 3959
  year: 2008
  ident: 140_CR33
  publication-title: Blood
  doi: 10.1182/blood-2008-05-155846
– volume: 16
  start-page: 270
  year: 2016
  ident: 140_CR29
  publication-title: BMC Cancer
  doi: 10.1186/s12885-016-2305-2
– volume: 280
  start-page: 4131
  year: 2013
  ident: 140_CR8
  publication-title: FEBS J
  doi: 10.1111/febs.12338
– volume: 66
  start-page: 17
  year: 1984
  ident: 140_CR1
  publication-title: Hum Genet
  doi: 10.1007/BF00275183
– volume: 91
  start-page: 8307
  year: 1994
  ident: 140_CR17
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.91.18.8307
– volume: 40
  start-page: 1074
  year: 2013
  ident: 140_CR32
  publication-title: J Rheumatol
  doi: 10.3899/jrheum.121389
– volume: 205
  start-page: 182
  year: 1994
  ident: 140_CR10
  publication-title: Proc Soc Exp Biol Med
  doi: 10.3181/00379727-205-43695
– volume: 24
  start-page: 6041
  year: 2015
  ident: 140_CR13
  publication-title: Hum Mol Genet
  doi: 10.1093/hmg/ddv323
– volume: 24
  start-page: 2923
  year: 2015
  ident: 140_CR39
  publication-title: Hum Mol Genet
  doi: 10.1093/hmg/ddv055
– volume: 20
  start-page: 1174
  year: 2014
  ident: 140_CR34
  publication-title: Nat Med
  doi: 10.1038/nm.3655
– volume: 132
  start-page: 2752
  year: 2012
  ident: 140_CR30
  publication-title: J Invest Dermatol
  doi: 10.1038/jid.2012.226
– volume: 90
  start-page: 717
  year: 1997
  ident: 140_CR20
  publication-title: Cell
  doi: 10.1016/S0092-8674(00)80532-2
– volume: 30
  start-page: 16
  year: 2011
  ident: 140_CR6
  publication-title: Acta Myol
– volume: 31
  start-page: 1445
  year: 2011
  ident: 140_CR27
  publication-title: Rheumatol Int
  doi: 10.1007/s00296-010-1500-8
– volume: 8
  start-page: 2471
  year: 2016
  ident: 140_CR23
  publication-title: Am J Transl Res
– volume: 1
  start-page: 21
  year: 2011
  ident: 140_CR5
  publication-title: Skelet Muscle
  doi: 10.1186/2044-5040-1-21
– volume: 8 Suppl 2
  start-page: S3
  year: 2006
  ident: 140_CR7
  publication-title: Arthritis Res Ther
  doi: 10.1186/ar1917
– volume: 24
  start-page: 3814
  year: 2015
  ident: 140_CR46
  publication-title: Hum Mol Genet
– volume: 98
  start-page: 911
  year: 2005
  ident: 140_CR11
  publication-title: J Appl Physiol (1985)
  doi: 10.1152/japplphysiol.01026.2004
– volume: 19
  start-page: 241
  year: 2009
  ident: 140_CR16
  publication-title: Neuromuscul Disord
  doi: 10.1016/j.nmd.2008.11.015
– volume: 16
  start-page: 2102
  year: 2016
  ident: 140_CR36
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2016.07.041
– volume: 2014
  start-page: 965631
  year: 2014
  ident: 140_CR4
  publication-title: Biomed Res Int
  doi: 10.1155/2014/965631
– volume: 3
  start-page: e12391
  year: 2015
  ident: 140_CR49
  publication-title: Physiol Rep
  doi: 10.14814/phy2.12391
– volume: 111
  start-page: 5723
  year: 2014
  ident: 140_CR18
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1323842111
– volume: 184
  start-page: 3094
  year: 2014
  ident: 140_CR40
  publication-title: Am J Pathol
  doi: 10.1016/j.ajpath.2014.07.007
– volume: 124
  start-page: 3654
  year: 2011
  ident: 140_CR45
  publication-title: J Cell Sci
  doi: 10.1242/jcs.086629
– volume: 14
  start-page: 20
  year: 2015
  ident: 140_CR19
  publication-title: Stem Cell Res
  doi: 10.1016/j.scr.2014.10.007
– volume: 23
  start-page: 4786
  year: 2014
  ident: 140_CR38
  publication-title: Hum Mol Genet
  doi: 10.1093/hmg/ddu194
– reference: 9288751 - Cell. 1997 Aug 22;90(4):717-27
– reference: 17162189 - Pediatr Neurol. 2007 Jan;36(1):1-7
– reference: 21798099 - Skelet Muscle. 2011 May 04;1(1):21
– reference: 15234960 - J Appl Physiol (1985). 2004 Nov;97(5):1970-7
– reference: 15542570 - J Appl Physiol (1985). 2005 Mar;98(3):911-7
– reference: 25678553 - Hum Mol Genet. 2015 May 15;24(10):2923-37
– reference: 22045730 - J Cell Sci. 2011 Nov 1;124(Pt 21):3654-64
– reference: 8108469 - Proc Soc Exp Biol Med. 1994 Feb;205(2):182-5
– reference: 17201070 - Exerc Immunol Rev. 2006;12:6-33
– reference: 27524611 - Cell Rep. 2016 Aug 23;16(8):2102-2115
– reference: 23529913 - Birth Defects Res B Dev Reprod Toxicol. 2013 Apr;98(2):170-82
– reference: 18664393 - Int Immunopharmacol. 2008 Nov;8(11):1595-601
– reference: 24781208 - Hum Mol Genet. 2014 Sep 15;23(18):4786-800
– reference: 6365739 - Hum Genet. 1984;66(1):17-40
– reference: 23637318 - J Rheumatol. 2013 Jul;40(7):1074-81
– reference: 23097179 - J Orthop Res. 2013 Mar;31(3):343-9
– reference: 20613637 - J Neuropathol Exp Neurol. 2010 Aug;69(8):771-6
– reference: 25194569 - Nat Med. 2014 Oct;20(10):1174-81
– reference: 25460248 - Stem Cell Res. 2015 Jan;14(1):20-9
– reference: 21842588 - Acta Myol. 2011 Jun;30(1):16-23
– reference: 24440156 - Biochim Biophys Acta. 2014 Oct;1840(10):3170-80
– reference: 27068103 - BMC Cancer. 2016 Apr 11;16:270
– reference: 25607927 - PLoS One. 2015 Jan 21;10(1):e0117306
– reference: 27621596 - Drug Des Devel Ther. 2016 Aug 30;10 :2745-58
– reference: 24634453 - Neurology. 2014 Apr 15;82(15):1302-6
– reference: 3319190 - Cell. 1987 Dec 24;51(6):919-28
– reference: 9593700 - J Biol Chem. 1998 May 29;273(22):13625-9
– reference: 25859011 - Hum Mol Genet. 2015 Jul 1;24(13):3814-29
– reference: 15616792 - Acta Neuropathol. 2005 Mar;109(3):285-93
– reference: 27398133 - Am J Transl Res. 2016 Jun 15;8(6):2471-89
– reference: 18784373 - Blood. 2008 Nov 15;112(10 ):3959-64
– reference: 16899107 - Arthritis Res Ther. 2006;8 Suppl 2:S3
– reference: 23663276 - FEBS J. 2013 Sep;280(17):4131-48
– reference: 26251044 - Hum Mol Genet. 2015 Nov 1;24(21):6041-53
– reference: 19217290 - Neuromuscul Disord. 2009 Apr;19(4):241-9
– reference: 24706788 - Proc Natl Acad Sci U S A. 2014 Apr 15;111(15):5723-8
– reference: 24877152 - Biomed Res Int. 2014;2014:965631
– reference: 8078878 - Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8307-13
– reference: 18996917 - Hum Mol Genet. 2009 Feb 1;18(3):482-96
– reference: 25658637 - PLoS One. 2015 Feb 06;10(2):e0118080
– reference: 21509823 - J Bone Miner Res. 2011 Aug;26(8):1891-903
– reference: 20473503 - Rheumatol Int. 2011 Nov;31(11):1445-9
– reference: 26137572 - EBioMedicine. 2015 Feb 26;2(4):285-93
– reference: 25174878 - Am J Pathol. 2014 Nov;184(11):3094-104
– reference: 22716658 - BMC Musculoskelet Disord. 2012 Jun 20;13:106
– reference: 25921779 - Physiol Rep. 2015 Apr;3(4):null
– reference: 22810302 - J Invest Dermatol. 2012 Dec;132(12):2752-61
– reference: 25194572 - Nat Med. 2014 Oct;20(10):1182-6
– reference: 20081842 - Nat Cell Biol. 2010 Feb;12(2):143-52
– reference: 20505827 - PLoS One. 2010 May 21;5(5):e10763
SSID ssj0000491078
Score 2.3268688
Snippet Chronic increases in the levels of the inflammatory cytokine interleukin-6 (IL-6) in serum and skeletal muscle are thought to contribute to the progression of...
Background Chronic increases in the levels of the inflammatory cytokine interleukin-6 (IL-6) in serum and skeletal muscle are thought to contribute to the...
BackgroundChronic increases in the levels of the inflammatory cytokine interleukin-6 (IL-6) in serum and skeletal muscle are thought to contribute to the...
Abstract Background Chronic increases in the levels of the inflammatory cytokine interleukin-6 (IL-6) in serum and skeletal muscle are thought to contribute to...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 23
SubjectTerms Animal models
Arthritis
Cardiac muscle
Care and treatment
Creatine
Creatine kinase
Cytokines
Degeneration
Diaphragm
Disease
Drug dosages
Duchenne muscular dystrophy
Duchenne's muscular dystrophy
Dystrophin
Embryos
Fibrosis
Health aspects
Immunoglobulin G
Inflammation
Inflammatory diseases
Interleukin 6
Interleukin 6 receptors
Kyphosis
Metabolism
Muscle regeneration
Muscular dystrophy
Musculoskeletal system
Myosin
Pathology
Physiological aspects
Quadriceps muscle
Rats
Rodents
Skeletal muscle
STAT3
Stem cells
Tissue engineering
Transcription
Transgenic animals
Utrophin
Vertebrae
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELfQnnhBwPgIDGQQAgkpatI4sfNYENOGEA-wSXuz_FkKq1MtDVL3x-xv3Z2TVo2Q4IW3yj5Xyd357nfJ5WdC3hjLRF4wlVpueMq0KFOlPFQpVgPg1VUmfGT7_FqdnLPPF-XF3lFf2BPW0wP3iptwgDC6RtI-P2Umt4pnTGudmzqz3BcOoy_kvL1i6mePe6GuEcNrzFxUkxaKMfwYOcdOS5al16NEFPn6_4zKe2lp3DK5l4OO75N7A3iks_6iH5A7Ljwkh7MAhfNyQ9_S2M4Zn5MfkpuzbQs5xWetFIAeBS0u0tMvaUUhzrkVlNtxSDd2Q5FnM3SIPOmy67tTqd2066sGDEF_LxRd9Z17YU7bX5CsALVHyUsH_zaP7NVoZLoIu3WLkE667S_rkKwCr2cJwekROT_-dPbxJB0OY0hNWbN1aouy0nmhnWcKrAhx0lrlMuWKyuhSeyO80wL58nmtWaGYAyTorTE-80qXvHhMDkIT3FNCp0qJrBCuFLliytS60KowTLMM0CEgnoRkW8tIMzCV44EZlzJWLKKSvTElGFPG5rTrhLzfLVn1NB1_E_6A5t4JIsN2HAC_k4PfyX_5XUJeo7NI5NAI2KQzV13bytPv3-SsRJ69EnBAQt4NQr6BOzBq-OYB9IC0WyPJo5EkbHIznt76pByCTCtzZAsEP2ciIa9207gSG-eCazqUKTmrM17nCXnSu_DuvqcwDuEbVvORc48UM54Jix-RghyKAORufPY_NPmc3J3itgRAMOVH5GB91bkXgPTW-mXc1LdsRVT0
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96vvgi6vlRPSWKKAhl223apE-yisediA96B_sW8tW9xdt03W6FvT_Gv9WZtFuvCPdWkklpM5OZ36TTXwh5YywTacZUbLnhMdMij5WqIEuxGgCvLhJRBbbPb8XJOfsyz-f9hlvTl1XufWJw1LY2uEc-SZEaDWIbEx_Wv2I8NQq_rvZHaNwmd5C6DK2az_mwxwLoF7Ib0X_MTEUxaSAlw1-SU6y3ZEl8NQpHgbX_f998LTiNCyevRaLj--ReDyHprNP5A3LL-YfkcOYhfV7t6FsaijrDbvkh-XO2LySnuONKAe5RmMtlfPo1Lih4O7eGpDs06druKLJt-hbxJ121XY0qtbtmu6lBHfT3UtF1V7_nF7T5CSELsHuQvHRwt0XgsEZV06Ufxi19PGn3V9YhZQU-zwpc1CNyfvz57NNJ3B_JEJu8ZNvYZnmh00y7iinQJXhLa5VLlMsKo3NdGVE5LZA1n5eaZYo5wIOVNaZKKqVznj0mB7727imhU6VEkgmXi1QxZUqdaZUZplkCGBFwT0SSvWak6fnK8diMSxnyFlHITpkSlClDidpVRN4PQ9YdWcdNwh9R3YMg8myHhnqzkP2ylRxsTpdIGVlNmUmt4gnTWqemTCyvMheR12gsEpk0PJbqLFTbNPL0x3c5y5FtLwc0EJF3vVBVwxsY1f_5APOA5FsjyaORJCx1M-7e26TsXU0j_y2MiLwaunEkls95V7cok3NWJrxMI_KkM-HhvafQDk4cRvORcY8mZtzjlxeBiBxSAWRwfHbzYz0nd6e44CDgT_kROdhuWvcCkNxWvwzL9S_ckUxo
  priority: 102
  providerName: ProQuest
Title Treatment with the anti-IL-6 receptor antibody attenuates muscular dystrophy via promoting skeletal muscle regeneration in dystrophin-/utrophin-deficient mice
URI https://www.ncbi.nlm.nih.gov/pubmed/29078808
https://www.proquest.com/docview/1960991048
https://www.proquest.com/docview/1957490791
https://pubmed.ncbi.nlm.nih.gov/PMC5660454
https://doaj.org/article/7099b97336f24c1da704bbb1c90d7f3e
Volume 7
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9NAEF71ceGCgPIwlGhBCCQkUztee-0DQilq1SKoUGmk3lb7cggkdohjRPpj-K3MrO2oFhXiFq1nrXgeu9-sx98Q8kIbloYRk77hmvtMpbEvZQ5ZilEAeFUSpLlj-zxLTsbsw2V8uUW69latAqsbUzvsJzVezt78-rF-BwH_1gV8mhxUkGfhd8YhFlGywL_aJruwMXFsaPCpRfvfGjAMyY7rURcw5sfgv-17zhvv0tupHKH_38v2tX2rX1N5bZM6vkNut-iSjhp3uEu2bHGP7I0KyKzna_qSunpPd5C-R35fdDXmFA9jKSBBCmqe-qcf_YTCQmgXkI-7IVWaNUUizqJGaErndVO-Ss26Wi1LsBT9OZV00ZT2FRNafYfdDDTqJGcW7jZx9NboBXRabOZNC_-g7n4Zi2wW-H_msHrdJ-Pjo4v3J37brcHXccZWvoniRIWRsjmTYGZYSI2RNpA2SrSKVa7T3KoUCfV5plgkmQWomBut8yCXKubRA7JTlIV9ROhQyjSIUhunoWRSZypSMtJMsQDgI0AijwSdZYRuqcyxo8ZMuJQmTURjTAHGFK567cojrzdTFg2Px7-ED9HcG0Gk4HYD5XIi2ogWHLC1ypBNMh8yHRrJA6aUCnUWGJ5H1iPP0VkEkmwUWMUzkXVVidMv52IUIxFfDEDBI69aobyEJ9Cy_SgC9IC8XD3J_Z4krAK6f7nzSdEFkQiRThB8nqUeeba5jDOxsq6wZY0yMWdZwLPQIw8bF9489xDGYX2H2bzn3D3F9K8U06-OoxyyBCR3fPw_SnhCbg0x7AARDPk-2Vkta_sUoN5KDcg2v-QDsnt4dPb5fOAOTAYuqP8AqGZW4g
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6VcoALAsojUGBBPCQkK36svfYBofCoEhp6gFbqbbsvh4jGDnECSn8MP4HfyMzaDrWQeuvN2p21bM_szDfr2W8Jea4NS4OISc9wzT2m0tiTMocsxSgAvCrx09yxfR4kwyP26Tg-3iJ_2r0wWFbZ-kTnqE2pcY28HyA1GsQ2lr6d__Dw1Cj8u9oeoVGbxb5d_4KUrXoz-gD6fRGGex8P3w-95lQBT8cZW3omihMVRMrmTMLjwIQ3Rlpf2ijRKla5TnOrUiR-55likWQWIE1utM79XKqYR3DfK-QqBF4fkz1-zDdrOoC2oTFtfp4GadKvIAXELdAB1ncy3zvrhD93SsD_seBcMOwWap6LfHs3yY0GstJBbWO3yJYtbpOdQQHp-mxNX1JXROpW53fI78O2cJ3iCi8FeElBd1NvNPYSCt7VziHJd02qNGuK7J7FCvEuna3qmlhq1tVyUYL66c-ppPO6XrCY0Oo7hEjIFZzkqYW7TRxnNpoWnRabcdPC66_aK2ORIgOfZwYu8Q45uhRl3SXbRVnY-4SGUqZ-lNo4DSSTOlORkpFmivmASQFn9Yjfakbohh8dj-k4FS5PShNRK1OAMoUriTvrkdebIfOaHOQi4Xeo7o0g8nq7hnIxEY2bEBxsXGVIUZmHTAdGcp8ppQKd-Ybnke2RZ2gsApk7CiwNmshVVYnR1y9iECO7Xwzoo0deNUJ5CW-gZbPTAr4Dkn11JHc7kuBadLe7tUnRuLZK_JuIPfJ0040jsVyvsOUKZWLOMp9nQY_cq014894htEPQgNG8Y9ydD9PtKabfHPE5pB7IGPng4sd6Qq4NDz-PxXh0sP-QXA9x8gHYCPku2V4uVvYRoMileuymLiUnl-0r_gICoYuh
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treatment+with+the+anti-IL-6+receptor+antibody+attenuates+muscular+dystrophy+via+promoting+skeletal+muscle+regeneration+in+dystrophin-%2Futrophin-deficient+mice&rft.jtitle=Skeletal+muscle&rft.au=Wada%2C+Eiji&rft.au=Tanihata%2C+Jun&rft.au=Iwamura%2C+Akira&rft.au=Takeda%2C+Shin%27ichi&rft.date=2017-10-27&rft.pub=BioMed+Central+Ltd&rft.issn=2044-5040&rft.eissn=2044-5040&rft.volume=7&rft.issue=1&rft_id=info:doi/10.1186%2Fs13395-017-0140-z&rft.externalDBID=ISR&rft.externalDocID=A511795067
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2044-5040&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2044-5040&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2044-5040&client=summon